Physician profile
Jonathan Koop
NPI 1184917833
$2,063.14
in general payments reported to CMS, 2019-2025
29 companies · $579 in 2025
The $579 reported for 2025 was more than what 83% of Obstetrics & Gynecology providers received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $141 · 2020: $36.64 · 2021: $226 · 2022: $398 · 2023: $381 · 2024: $301 · 2025: $579.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,187 · Education: $74.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,186.60 |
| Education | $74.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $212.44 | 2019-2023 | |
| Astellas Pharma US INC | $211.37 | 2023-2025 | Veozah, Myrbetriq |
| Exeltis, USA INC. | $170.52 | 2019-2025 | Slynd |
| Gynesonics, INC. | $166.14 | 2022-2023 | Sonata Sonography-Guided Transcervical Fibroid Ablation System |
| Ethicon US, LLC | $128.32 | 2021-2025 | Vistaseal |
| Meditrina | $94.19 | 2022 | |
| Hologic Sales and Service, LLC | $92.80 | 2021-2025 | Myosure Tissue Removal Device, Acessa Provu System, Novasure |
| Dexcom, INC. | $88.81 | 2025 | Dexcom G6 Transmitter |
| Mayne Pharma Commercial LLC | $87.24 | 2024-2025 | |
| Sage Therapeutics, LLC | $80.83 | 2024-2025 | Zurzuvae |
| Daiichi Sankyo INC. | $72.10 | 2025 | Injectafer |
| Channel Medsystems, INC. | $63.62 | 2023 | |
| Aspira Women'S Health INC | $58.21 | 2021 | |
| Pacira Pharmaceuticals Incorporated | $55.71 | 2025 | Exparel |
| Pfizer INC. | $48.83 | 2022-2024 |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Therapeuticsmd, INC. | $48.78 | 2019-2022 | |
| Abbott Laboratories | $45.17 | 2022 | |
| Shield Therapeutics INC | $42.46 | 2023-2024 | Accrufer |
| Biotissue Holdings INC. | $41.72 | 2025 | |
| Conmed Corporation | $39.71 | 2023 | Airseal |
| Mylan Pharmaceuticals INC. | $38.47 | 2021-2022 | |
| Octapharma USA, INC. | $34.99 | 2025 | Fibryga |
| Merck Sharp & Dohme LLC | $31.07 | 2023 | Gardasil 9 |
| Bayer Healthcare Pharmaceuticals INC. | $26.35 | 2021-2025 | |
| Avion Pharmaceuticals | $25.49 | 2019-2020 | |
| Exact Sciences Corporation | $15.75 | 2023 | Cologuard Collection Kit |
| Agile Therapeutics, INC. | $14.92 | 2023 | Twirla |
| Coopersurgical, INC. | $14.71 | 2021 | |
| Duchesnay USA Incorporated | $12.42 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jonathan Koop listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.